Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling.

T. Lindmo,P. Bunn

DOI: https://doi.org/10.1016/0076-6879(86)21067-8

Methods in Enzymology

Abstract:

What problem does this paper attempt to address?

[A Case of Long-Term Survival after Surgeries for Gastric Cancer and Metachronous Ovarian Metastasis]

Tatsuya Yoshida,Naoki Wajima,Harue Akasaka,Shingo Sakuraba,Takahiro Muroya,Norihito Kubo,Kensuke Okano,Chiaki Uchida,Kenichi Hakamada

Abstract:The patient was a 57-year-old woman. In October 2011, she underwent distal gastrectomy, D2 lymphadenectomy, and Roux-en-Y reconstruction for gastric cancer (pT4a, pN3b, Stage ⅢC [JCGC 14th Edition]). She then received S-1 plus CDDP combination therapy and S-1 monotherapy as postoperative adjuvant chemotherapies for 1 year, and was followed up as an outpatient. In April 2013, a significant increase in the CA19-9 level was noted, and CT indicated a right ovarian tumor. Ovarian metastasis from the gastric cancer was diagnosed, and the response to 3 courses of weekly PTX was stable disease. No findings indicated metastasis to other organs. In July 2013, a salpingo-oophorectomy was performed, after which her CA19-9 level returned to the normal range. Follow-up was adopted as the postoperative strategy in part due to the desires of the patient. Presently, 3 years and 6 months after the initial surgery and 1 year and 9 months after the last surgery, no recurrence has been detected. Generally, ovarian metastasis from gastric cancer is considered to be associated with a poor prognosis. However, our patient showed long-term survival after surgeries for gastric cancer and asynchronous ovarian metastasis. Here, we report the details of our case and review the relevant literature.
[Long-Term Survival of an Adolescent and Young Adult Patient with Unresectable Advanced Gastric Cancer in Whom Multidisciplinary Treatment Was Effective]

Tsutomu Namikawa,Masato Utsunomiya,Keiichiro Yokota,Yasuhiro Kawanishi,Sachi Yamaguchi,Masaya Munekage,Hiromichi Maeda,Hiroyuki Kitagawa,Yusuke Nagata,Michiya Kobayashi,Kazuhiro Hanazaki,Satoru Seo

Abstract:We report the case of a long-term-surviving adolescent and young adult patient with unresectable advanced gastric cancer for whom multidisciplinary treatment was effective. A 29-year-old woman was referred to our hospital for further examination following a diagnosis of gastric cancer by a local physician. Esophagogastroduodenoscopy showed a deep ulcerated lesion in the lower third of the stomach, and analysis of biopsy specimens revealed an adenocarcinoma. Abdominal contrast- enhanced computed tomography showed gastric wall thickening in the lower third of the stomach. The patient underwent distal gastrectomy with lymph node dissection, including resection of localized peritoneal metastases, followed by Roux-en- Y reconstruction. The pathological diagnosis was serosa-invading poorly differentiated adenocarcinoma with 1 lymph node metastasis measuring 6.0×5.5 cm in the posterior wall of the lower third of the stomach and negative immunohistochemical staining for human epidermal growth factor receptor 2. The patient received postoperative chemotherapy with S-1 and oxaliplatin. She developed bilateral ovarian metastases measuring 13.0 cm and 7.8 cm after 17 months. The patient presented with severe lower abdominal pain and underwent an emergency bilateral ovarian metastasectomy, which revealed torsion of the right ovarian tumor, which had twisted twice on its pedicle, and a left ovarian mass. After the operation, 41 courses of ramucirumab with nab-paclitaxel were administered as a second-line treatment, and she received systemic drug treatment. Sixty months after the gastrectomy, the patient developed left hydronephrosis due to peritoneal metastases and was treated with nivolumab after ureteral stent replacement. No effective treatment was proposed in cancer multigene panel testing, and she died 66 months after the initial treatment because of disease progression. Comprehensive multidisciplinary treatment, including surgical and local therapy for peritoneal dissemination based on drug therapy for unresectable advanced gastric cancer, may result in long-term survival. Further research and accumulation of such cases would lead to the development of novel treatments.
Survival Analysis of Gastric Stump Cancer:A Report of 37 Cases

陈力,田华,何志刚,陶思丰,彭淑牖

DOI: https://doi.org/10.3760/cma.j.issn.1671-0274.2004.03.014

2004-01-01

Abstract:Objective To study the effect of surgical treatment on the prognosis of gastric stump cancer patients. Methods From Jan. 1993 to 2003 March, 37 patients with gastric stump cancer received surgical operation in our hospital. The patients were divided into early stage and advanced groups,radical and palliative groups respectively. Clinical data and survival were analyzed retrospectively. Results There were 9(24.3%) early cases and 28(75.7%) cases with advanced stump cancer. The postoperative cumulative 5 year survival rate of the patients with early staged gastric stump cancer was significantly higher than those with advanced cancer (55.3%vs 16.5%,P 0.01). Twenty one (56.8%) patients received radical resection. The median survival time was 40.3 months in radical group and 13.0 months in palliative group(P 0.01). Conclusions It is necessary to carry out the periodic endoscopic examination in the patients who have received gastrectomy for benign gastric diseases. The reasonable radical resection is an effective way to prolong the postoperative survival time in gastric stump cancer.
Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report

Koki Hayashi,Minoru Kitago,Yuta Abe,Hiroshi Yagi,Yasushi Hasegawa,Shutaro Hori,Masayuki Tanaka,Yutaka Nakano,Keisuke Asakura,Yohei Masugi,Yuko Kitagawa

DOI: https://doi.org/10.1097/MD.0000000000035856

2023-11-17

Abstract:Introduction: Pancreatic cancer (PC) is highly malignant and metastatic; however, bone metastases are rare. Although the effectiveness of conversion surgery for distant metastases of PC has been reported in a few cases, there are no reports on surgical resection for bone metastases. Here, we report a case of long-term survival after resection of bone metastasis from PC. Patient concerns: A 60-year-old woman underwent pancreaticoduodenectomy after neoadjuvant chemoradiotherapy for pancreatic head cancer. At 28 months after surgery, multiple lung metastases from PC were diagnosed, and chemotherapy was administered. After 59 months, chemotherapy was terminated because all target lesions had disappeared on imaging. Diagnosis: At 77 months after the initial surgery, bone metastasis in the left 9th rib was detected by positron emission tomography/computed tomography, which was performed due to elevated carbohydrate antigen 19-9 levels. Interventions: Chemotherapy was readministered as the initial treatment. Subsequently, due to the long-term well-controlled status of the recurrence site and the absence of other metastases, thoracoscopic-assisted partial resection of the left 9th rib was performed 128 months following pancreaticoduodenectomy. Pathological examination revealed adenocarcinoma metastasis from PC. Outcomes: The patient is currently alive without recurrence 44 months after resection for bone metastasis and 172 months after the initial surgery. Conclusion: Surgical resection may be favorable in patients with bone metastasis of PC that is well-controlled with chemotherapy.
[Advanced Gastric Cancer with Virchow's Lymph Node Metastasis-A Long-Term Survival Case]

Terutada Kobayashi,Ryuichiro Sato,Naoyuki Kaneko,Jun Sato,Yoichiro Kakugawa,Yuji Funayama

Abstract:A 36-year-old woman presented to our hospital with a complaint of melena. Examinations revealed type 3 gastric cancer with left supraclavicular lymph node(Virchow's node)and para-aortic lymph node(PAN)metastases. The patient was treated with S-1 and CDDP combination chemotherapy. After 2 courses of chemotherapy, the lymph node metastases were significantly reduced. Subsequently, a total gastrectomy with D2 plus PAN dissection was performed. Histopathological examination revealed the complete absence of cancer cells in both the primary lesion of the stomach and all dissected lymph nodes. No additional surgery or radiation therapy was performed for Virchow's node metastasis. Postoperatively, she received S-1 chemotherapy for 2.5 years. She remains well 9.5 years after the surgery, without any evidence of recurrent disease.
Neurotrophins regulate sequential changes in neurotrophin receptor expression by sympathetic neuroblasts

J. Verdi,D. Anderson

DOI: https://doi.org/10.1016/0896-6273(94)90421-9

IF: 16.2

1994-12-01

Neuron

Abstract:
Fluid closures which mimic wave-praticle interactions in strong Langmuir turbulence.

Goldman,Newman,Perkins

DOI: https://doi.org/10.1103/PHYSREVLETT.70.4075

IF: 8.6

1993-06-28

Physical Review Letters

Abstract:A new two-time-scale model of strong Langmuir turbulence has been constructed, using higher-moment fluid equations with dissipative closures designed to better simulate Vlasov theory predictions of linear wave properties, and to treat collisionless heating of particles by waves. Numerical solutions are carried out in a study of electron heating associated with collapse and burnout of a large-amplitude initial Langmuir wave and in a study of radiation-driven Langmuir turbulence interacting with ion-acoustic [ital quasimodes] in plasmas with [ital T][sub [ital e]][approx][ital T][sub [ital i]].
Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review

Hirotaka Suto,Yumiko Inui,Atsuo Okamura

DOI: https://doi.org/10.3389/fonc.2024.1449212

2024-08-06

Abstract:Background: Bone marrow metastasis (BMM) of gastric cancer (GC), which is the most common cause of disseminated intravascular coagulation (DIC) among solid tumors, has a poor prognosis. Studies on prognostic improvement beyond one year in patients with GC with BMM are limited. This is the first report of a patient who survived over three years after 30 months of S-1 plus oxaliplatin (SOX) therapy for GC with BMM. Case report: The patient was a 72-year-old woman who presented with anemia and high levels of alkaline phosphatase (ALP) and carbohydrate antigen 19-9 (CA19-9). Detailed examination led to the diagnosis with BMM of GC uncomplicated by DIC and the SOX regimen was initiated in November 2018. After six cycles, she was switched to S-1 monotherapy, and both ALP and CA19-9 levels reached normal by November 2019. However, computed tomography in April 2021 showed multiple bone metastases. Therefore, she was switched to paclitaxel-based therapy. In November 2021, the patient was further switched to nivolumab monotherapy, but she succumbed due to DIC in March 2022. Conclusion: GCs with BMM are prone to DIC, and the SOX regimen, which includes S-1 with efficacy against micrometastases, may constitute a safe and effective treatment modality.
Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review

Qingwei Li,Xuejun Xu,Dan Su,Tianshuo Zhou,Guangyu Wang,Zhiwei Li

DOI: https://doi.org/10.1186/s12885-019-5683-4

IF: 4.638

2019-05-16

BMC Cancer

Abstract:<h3>Background</h3><p>Gastric cancer ranks the fifth most common cancer, and the third leading cause of cancer-related deaths worldwide. Gastric cancer with liver metastasis (GCLM) has devastating prognosis, however, optimal treatment of GCLM, especially in elderly patients, has yet to be clarified.</p><h3>Case presentation</h3><p>A 75-year-old man was diagnosed with advanced gastric cancer (GC), presenting with acute gastrointestinal bleeding and synchronous metastatic lesion in liver. Based on multidisciplinary team (MDT)'s decision, this patient underwent distal palliative gastrectomy with R1 margin. Histopathological diagnosis was stage IV gastric adenocarcinoma (pT3N2M1), HER2 negative. The patient was treated with chemotherapy and argon-helium cryoablation of liver and lung metastases.HER-2 gene amplification was identified in peripheral blood at later stage of therapy. The patient had been followed-up for 39 months, in sharp contrast to a median survival time of 13.8 months for majority of advanced GC.</p><h3>Conclusions</h3><p>Palliative distal gastrectomy in combination with chemotherapy and cryoablation significantly prolongs overall survival of an elderly patient with GCLM.</p>

oncology
Pathological Complete Response and Long-Term Survival in a Very Elderly Patient after Neoadjuvant Chemotherapy for Locally Advanced, Unresectable Gastric Cancer

Kunihiko Izuishi,Mitsuyoshi Kobayashi,Takanori Sano,Hirohito Mori,Kazuo Ebara

DOI: https://doi.org/10.1155/2014/532924

2014-01-01

Case Reports in Oncological Medicine

Abstract:We address the pathological complete response and long-term survival of elderly patients after neoadjuvant chemotherapy in locally advanced, unresectable gastric cancer. An 83-year-old man was hospitalized for upper abdominal pain. Gastrointestinal endoscopy showed a large tumor spanning from the gastric angle to the antrum, and extending to the duodenum. Histological analysis of the biopsy specimen revealed a poorly differentiated adenocarcinoma. Computed tomography images showed thickening of the gastric wall and invasion of the body and head of the pancreas, but did not show distant metastases. The patient was diagnosed with unresectable gastric cancer, and was treated with neoadjuvant chemotherapy using S-1 (80 mg/m 2 ) and paclitaxel (60 mg/m 2 ). After the third course of chemotherapy, gastrointestinal endoscopy and abdominal computed tomography revealed a remarkable reduction in tumor size. This reduction allowed distal gastrectomy to be conducted. Histological examination of the specimen revealed no cancer cells in the primary lesion or lymph nodes. The patient was treated with adjuvant chemotherapy of oral tegafur-uracil (300 mg/day) for one year after surgery. He lived for five years after surgery without recurrence. Neoadjuvant chemotherapy using S-1 and paclitaxel is a potent strategy for improving survival in very elderly patients with unresectable gastric cancer.
Long-term Survival of Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasm: Two Case Reports.

Lun-Tao Woo,Yong-Feng Ding,Chen-Yu Mao,Jiong Qian,Xiu-Ming Zhang,Nong Xu

DOI: https://doi.org/10.12998/wjcc.v10.i22.7936

2022-01-01

World Journal of Clinical Cases

Abstract:BACKGROUND:Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN), which consists of neuroendocrine and non-neuroendocrine components, is quite rare. Until now, most data on gastric MiNEN come from clinical cases, without large-scale retrospective studies or controlled clinical trials. Consequently, no consensus regarding the origin, molecular characteristics, or appropriate treatment of MiNEN has been reached so far. We conducted chemotherapy of irinotecan plus cisplatin (IP regimen) and surgery in two patients with gastric MiNEN, which had never been used in treating this kind of tumor, leading to their long-term survival for more than 3 and 7 years, respectively.CASE SUMMARY:We present two patients (one male and one female) with gastric MiNEN, with the primary manifestation of recurrent upper abdominal pain. After they were referred to our hospital, a diagnosis of gastric MiNEN was defined with the help of CT scan, and histopathological and immunohistochemical examinations on the samples of gastrointestinal endoscopy or radical surgery. The male patient (case 1) were found to have metastases in the reginal lymph nodes and the left liver. He received four cycles of IP regimens first, then the gastrectomy and partial left liver resection, followed by additional two cycles of IP chemotherapy. The female patient (case 2) underwent a laparoscopic gastrectomy, and received six cycles of IP regimen. She was found to have metastatic lesions in the right lung 2 years after that, and underwent video-assisted thoracoscopic surgery (VATS) of the lower lobe of the right lung. The two patients have now survived for more than 3 years and 7 years, respectively, without any evidence of recurrence or metastases.CONCLUSION:IP regimen, combined with curative-intent surgery if feasible, could be considered as the priority in the choice of front-line chemotherapy for gastric MiNEN.
Surgical Management of Gastric Stump Cancer: a Report of 37 Cases

Chen Li,Tian Hua,Chen Jian,He Zhi-gang,Tao Si-feng,Lokesh Gurung,Peng Shu-you

DOI: https://doi.org/10.1631/jzus.2005.b0038

2005-01-01

Abstract:OBJECTIVE:To observe the clinicopathological characteristics of gastric stump cancer (GSC) and evaluate the benefits of radical surgery of GSC.METHODS:The clinicopathological characteristics and postoperative survival time of 37 GSC patients who underwent surgery were investigated retrospectively. The survival time was compared according to the type of surgical operation (radical resection vs palliative operation). Twenty-one cases that received radical resection were analyzed based on the pTMN stage. Survival curves were traced by using Kaplan-Meier methods.RESULTS:Most GSC (32/37) was detected in patients who had received Billroth II reconstruction after partial gastrectomy for benign gastric disease. The lesser curvature side and the suture line of anastomosis were the most frequent sites where GSC occurred (27/37). Differentiated adenocarcinoma was the dominant histopathological type (24/37). The postoperative 5-year survival rate of early stage GSC patients (n=9) was significantly higher than advanced stage GSC (n=12) (55.6% vs 16.5%, xL2=11.48, P<0.01). Five-year survival rate of 21 GSC patients with radical resection were 75% (3/4) for stage I, 60% (3/5) for stage II, 14.2% (1/7) for stage III, and 0% (0/5) for stage IV respectively. The median survival time of 21 GSC patients who underwent radical resection was longer than those undergoing palliative operation (43.0 m vs 13.0 m, x L2=36.31, P<0.01), the median survival time of stage IV patients with radical resection was 23.8 months.CONCLUSIONS:Without remote metastasis, radical resection for GSC is possible, and is an effective way to improve the prognosis of GSC. Even in stage IV GSC, radical resection can still prolong the survival time. It is necessary for the patients with benign gastric diseases who received partial gastrectomy to carry out the endoscopy follow-up, especially in patients with Billroth II reconstruction procedure at 15-20 years.
Long-term Survival of a Patient with Scalp Angiosarcoma and Multiple Metastases Treated Using Combination Therapy: A Case Report.

Jun Ye,Xiao-Fen Li,Yong-Dong Wang,Ying Yuan

DOI: https://doi.org/10.3892/ol.2015.2919

2015-01-01

Oncology Letters

Abstract:Angiosarcoma is a rare and deadly malignancy originating from the vascular endothelial cells. Surgery is the most effective method to cure this disease, but for metastatic angiosarcoma, a chemotherapy-based treatment is the main therapeutic choice. However, there is currently no standard chemotherapy regimen. The current study reports the case of a 66-year-old male with post-operative scalp angiosarcoma recurrence and multiple metastases. The patient obtained a complete response to first-line combination chemotherapy consisting of cyclophosphamide, epirubicin, vincristine and dacarbazine, with a progression-free survival time of eight months. After benefitting from subsequent comprehensive treatment including, cyclophosphamide, epirubicin, vincristine, dacarbazine, docetaxel, cisplatin, gemcitabine and radiotherapy and anti-angiogenic therapy, the patient obtained an overall survival time of 38 months following initial diagnosis.
A Monte Carlo analysis of peritoneal antimicrobial pharmacokinetics.

S. Hota,P. Crooke,J. Hotchkiss

DOI: https://doi.org/10.1007/978-1-4419-7046-6_40

Advances in experimental medicine and biology

Abstract:
Surgical Resection of Advanced Gastric Cancer Following Trastuzumab/Oxaliplatin/Capecitabine Combination Therapy

Cai-Xia Dong,Jian-Fei Fu,Xian-Yun Ye,Xiao-Fen Li,Xian Zhong,Ying Yuan

DOI: https://doi.org/10.3748/wjg.v20.i34.12355

IF: 5.374

2014-01-01

World Journal of Gastroenterology

Abstract:Late-stage gastric adenocarcinoma patients have a poor prognosis because of high recurrence rates. To improve long-term outcomes, perioperative chemotherapies are combined with surgery. Human epidermal growth factor receptor 2 (HER2) overexpression had been noted in gastric cancer; therefore, trastuzumab has been used occasionally in this setting. A 63-year-old male Chinese patient, who was diagnosed with adenocarcinoma in the gastric antrum, as well as lymph node metastases along the left gastric and hepatic artery, and left adrenal area, was admitted to our hospital. HER2 expression was positive, and cluster amplification was detected in a fluorescence in situ hybridization assay. The patient received three cycles of a neoadjuvant trastuzumab/oxaliplatin/capecitabine regimen. He subsequently underwent distal gastrectomy, D2+ lymphadenectomy, left adrenalectomy, cholecystectomy and Billroth. anastomosis. Treatment was continued with another five postoperative cycles of the same medication and trastuzumab application for 1 year. No recurrence has been observed 18 mo after the operation. Trastuzumab as perioperative and adjuvant medication, in combination with oxaliplatin and capecitabine for a HER2-overexpressing advanced gastric adenocarcinoma, led to recurrence-free survival of at least 18 mo after surgery. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report

Kosuke Fukuda,Takaaki Arigami,Koki Tokuda,Shigehiro Yanagita,Daisuke Matsushita,Yota Kawasaki,Satoshi Iino,Ken Sasaki,Akihiro Nakajo,Mari Kirishima,Akihide Tanimoto,Hitoshi Tsubouchi,Hiroshi Kurahara,Takao Ohtsuka

DOI: https://doi.org/10.1186/s40792-022-01412-x

2022-04-01

Surgical Case Reports

Abstract:Abstract Background In recent years, conversion surgery after chemotherapy has been considered a promising strategy for improving the prognosis of patients with stage IV gastric cancer. However, there are few reports on conversion gastrectomy after second-line chemotherapy. Here, we report a case of long-term survival of a patient with liver metastases from gastric cancer who underwent conversion surgery after second-line chemotherapy with ramucirumab and paclitaxel. Case presentation A 77-year-old man complaining of weight loss was diagnosed with human epidermal growth factor receptor 2-positive gastric cancer with multiple liver metastases. Although the patient initially received trastuzumab-based chemotherapy, it was discontinued, because he experienced trastuzumab-induced infusion reactions. Thereafter, he was treated with six courses of S-1 plus cisplatin and six courses of ramucirumab plus paclitaxel as the first- and second-line regimens, respectively. The primary tumor and liver metastases remarkably shrank, and the reduction rate of the measurable metastatic liver lesions was 81.1%. According to the Response Evaluation Criteria in Solid Tumors, the patient responded partially. Therefore, he underwent total gastrectomy with D2 lymphadenectomy and partial hepatectomy of segments 3 and 4. Pathological examination revealed tumor invasion into the muscularis propria, a grade 1a histological response, and no lymph node metastases. No viable cancer cells were identified in the specimens resected from liver segments 3 and 4. Accordingly, the patient was pathologically diagnosed with stage IB (ypT2N0M0). Postoperatively, the patient received adjuvant chemotherapy with S-1 for 6 months, and he survived without recurrence for 42 months after conversion surgery. Conclusions Conversion surgery might be clinically useful for improving survival in certain patients with gastric cancer, including those who previously received second-line chemotherapy.
[A Case of Unresectable Advanced Gastric Cancer Treated with Palliative Radiation Therapy for Massive Bleeding]

Ryohei Kawabata,Chizu Kameda,Akihiro Takata,Akinobu Yasuyama,Tae Matsumura,Chikato Koga,Masahiro Murakami,Masaki Hirota,Shingo Noura,Junzo Shimizu,Masashi Chatani,Yuki Imai,Junichi Hasegawa

Abstract:The patient was a 77-year-old man. He was diagnosed with Stage IV gastric cancer with pancreatic invasion and pyloric stenosis. After gastrojejunostomy, S-1 monotherapy was started. Melena and fatigue appeared 2 months after chemotherapy, and Grade 3 anemia was confirmed. Palliative radiotherapy of 30 Gy in 10 Fr was administered to control bleeding from the lesion. The progression of anemia stopped and outpatient chemotherapy became possible. Palliative radiotherapy for persistent bleeding from unresectable advanced gastric cancer is considered an effective treatment option to control bleeding.
Long-term survivor who underwent surgical resections of repeated peritoneal oligometastases from colon cancer : a rare case report

Takayuki Minami,Hideo Miyake,Hidemasa Nagai,Yuichiro Yoshioka,Koji Shibata,Daigoro Takahashi,Norihiro Yuasa,Masahiko Fujino

DOI: https://doi.org/10.2152/jmi.69.302

Abstract:A 74-year-old woman underwent right hemicolectomy and partial ileal resection for ascending colon cancer with synchronous peritoneal metastasis. Histopathological examination showed moderately differentiated adenocarcinoma with mucinous component, pT4b N3 M1, and Stage IV. Postoperative chemotherapy comprising 36 courses of mFOLFOX6 with bevacizumab was administered. Twenty-two months after the surgery, computed tomography (CT) revealed a 20 mm nodular lesion adjacent to the gastric wall, and laparoscopic resection of the nodule was performed. Thirty-nine months after the second surgery, CT showed a 24 mm nodular lesion involving the liver parenchyma, and partial hepatectomy involving the nodule was performed. Histopathological examination of the nodules resected by the second and third surgeries showed the same features as the primary ascending colon cancer. The nodules were diagnosed as metachronous peritoneal metastases. The patient followed up without chemotherapy after the second and third surgery, showed no recurrence for 26 months after the third surgery. Fortunately, more than 7 years have passed since the primary tumor resection. Hence, surgical resection for synchronous and repeated metachronous peritoneal oligometastases from colon cancer can offer long-term survival. J. Med. Invest. 69 : 302-307, August, 2022.
[A Case of Advanced Right Renal Pelvic Cancer with Left Supraclavicular Lymph Node Metastasis that Attained Long-Term Survival by Multidisciplinary Treatments]

Kazuto Imai,Takahiro Inoue,Ryoichi Saito,Takayuki Goto,Atsuro Sawada,Shusuke Akamatsu,Hiromitsu Negoro,Takashi Kobayashi,Naoki Terada,Toshinari Yamasaki,Kazutoshi Okubo,Koji Yoshimura,Akihiro Kanematsu,Osamu Ogawa

DOI: https://doi.org/10.14989/ActaUrolJap_65_1_13

Abstract:A man in his 70s was referred to our hospital for further examination of a positive occult blood finding. Imaging studies showed that the patient had right renal pelvic cancer with interaortocaval, multiple paracaval and left supraclavicular lymph node metastases (cT3N2Ml). Induction chemotherapy was performed with 5 cycles of MEC (methotrexate/epirubicin/cisplatin) followed by 2 cycles of GT (gemcitabine/paclitaxel). After the combined chemotherapies, the residual lesions were the primary tumor in the right renal pelvis and the left supraclavicular lymph node. Right total nephroureterectomy combined with lymph node dissection of paraaortic, paracaval, and interaortocaval area and left cervical area were performed. Histopathologically the postoperative T stage of the primary tumor was determined as ypT3. As for lymph nodes dissected, an interaortocaval lymph node alone, but not the other nodes, contained viable cancer cells. Adjuvant chemotherapy was performed with 7 courses of GT therapy. The patient had intravesical recurrence once and received transurethral resection of bladder tumor followed by intravesical instillations of Bacillus Calmette-Guerin (BCG). Finally, the patient has been free from recurrence for 10 years after the final treatment.
Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery

Peilin Dai,Xi Rao,Xi Zhang,Enming Qiu,Gang Wu,Yu Lin,Sitong Li,Zhou Li,Zhai Cai,Shuai Han

DOI: https://doi.org/10.3389/fimmu.2022.908558

IF: 7.3

2022-06-30

Frontiers in Immunology

Abstract:Metastatic advanced gastric cancer, for which treatment strategies are extremely limited, has a poor prognosis. Complete remission is rare. Patients usually lose the opportunity of therapeutic surgery because the lesions cannot be completely removed, although it can greatly prolong their survival time. Palliative surgery usually suggests bad outcomes. In recent years, the immune checkpoint inhibitor (ICI) nivolumab has shown significant efficacy in the treatment of advanced gastric cancer. However, its applicable conditions and optimal withdrawal time remain controversial owing to its low response rate and high incidence of immune-related adverse events. Herein, we introduce a 66-year-old male patient with advanced gastric cancer with multiple liver metastases who underwent laparoscopic total gastrectomy for acute gastric bleeding. The patient received eight cycles of S-1 plus oxaliplatin (SOX) and switched to eight cycles of SOX plus nivolumab combined regimen in a stable state, later achieving complete remission. There was no recurrence for 32 months after the surgery. This is the first reported case of gastric cancer with multiple liver metastases with long-term complete remission with nivolumab treatment after palliative surgery. The potential mechanism of complete remission was discussed through clinical, genomic, and immune characteristics. The patient had a history of psoriasis and was positive for programmed death ligand 1 (PD-L1), and the interaction of TP53 mutation and HER-2 (-) gene may be associated with complete remission.

immunology

Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling.

[A Case of Long-Term Survival after Surgeries for Gastric Cancer and Metachronous Ovarian Metastasis]

[Long-Term Survival of an Adolescent and Young Adult Patient with Unresectable Advanced Gastric Cancer in Whom Multidisciplinary Treatment Was Effective]

Survival Analysis of Gastric Stump Cancer:A Report of 37 Cases

Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report

[Advanced Gastric Cancer with Virchow's Lymph Node Metastasis-A Long-Term Survival Case]

Neurotrophins regulate sequential changes in neurotrophin receptor expression by sympathetic neuroblasts

Fluid closures which mimic wave-praticle interactions in strong Langmuir turbulence.

Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review

Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review

Pathological Complete Response and Long-Term Survival in a Very Elderly Patient after Neoadjuvant Chemotherapy for Locally Advanced, Unresectable Gastric Cancer

Long-term Survival of Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasm: Two Case Reports.

Surgical Management of Gastric Stump Cancer: a Report of 37 Cases

Long-term Survival of a Patient with Scalp Angiosarcoma and Multiple Metastases Treated Using Combination Therapy: A Case Report.

A Monte Carlo analysis of peritoneal antimicrobial pharmacokinetics.

Surgical Resection of Advanced Gastric Cancer Following Trastuzumab/Oxaliplatin/Capecitabine Combination Therapy

Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report

[A Case of Unresectable Advanced Gastric Cancer Treated with Palliative Radiation Therapy for Massive Bleeding]

Long-term survivor who underwent surgical resections of repeated peritoneal oligometastases from colon cancer : a rare case report

[A Case of Advanced Right Renal Pelvic Cancer with Left Supraclavicular Lymph Node Metastasis that Attained Long-Term Survival by Multidisciplinary Treatments]

Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery